top of page

Piramal Pharma moves to acquire remaining 26% of biologics CDMO Yapan Bio

Writer: nuaxia
nuaxia
2 minutes ago
2 min read

The proposed purchase would increase Piramal Pharma's ownership of the vaccines and biologics CDMO from 74% to 100%, with final consideration and completion terms still under discussion.


On 18 November 2026, Piramal Pharma disclosed that its authorised board committee had approved exercising a call option to acquire the remaining 26% equity stake in Yapan Bio from existing shareholders.


If completed, the transaction would make Yapan Bio a wholly owned subsidiary of Piramal Pharma, although purchase consideration, definitive transaction terms and the effective share-transfer date have not yet been finalised.

Field

Content

Alert Type

Deal

Companies

Piramal Pharma Limited; Yapan Bio Private Limited

Deal Type

Proposed acquisition of remaining minority equity stake through exercise of call option

Asset or Company

Remaining 26% equity stake in Yapan Bio Private Limited

Therapy Area(s)

Vaccines; biologics; biopharmaceutical development and manufacturing

Technology or Modality

Contract development and manufacturing services including biologics process development, characterisation and Phase I/II GMP manufacturing

Deal Value

Purchase consideration not disclosed; final acquisition terms and effective transfer date have not been finalised.

Geography

India

What Happened

Piramal Pharma's authorised board committee approved exercising a call option to acquire the remaining 26% shareholding in Yapan Bio. The company is discussing the steps required to complete the proposed transaction with existing shareholders.

Why It Matters

Completion would increase Piramal Pharma's holding in Yapan Bio from 74% to 100%, consolidating ownership of a business providing specialist vaccines and biologics development and manufacturing services.

Supporting Context

Yapan Bio specialises in process development, characterisation and Phase I/II GMP manufacturing for vaccines and biologics. Piramal Pharma already owns 74% of the company.

Strategic Rationale

Full ownership would consolidate control of Yapan Bio's specialised biologics CDMO operations within Piramal Pharma, subject to completion of the proposed acquisition.

Potential Impact

If completed, Yapan Bio would become a wholly owned subsidiary and Piramal Pharma would hold the entire equity interest. Any operational or financial effects beyond this remain unquantified.

Key Takeaway

Piramal Pharma has approved exercising its option to acquire the remaining 26% of Yapan Bio, but the acquisition has not been completed and financial terms remain outstanding.

What to Watch

Agreement on purchase consideration, execution of definitive documentation, completion of the share transfer and subsequent stock-exchange disclosures.

Primary Source

https://nsearchives.nseindia.com/corporate/Priyankamehta_18112026171520_SE_Disclosure_Call_Option_Exercise.pdf

Relevant Date

18 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page